Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2024 Dec;26(12):1427-1437.
doi: 10.1007/s11886-024-02138-y. Epub 2024 Oct 1.

Cardiovascular Outcomes of Uric Acid Lowering Medications: A Meta-Analysis

Yasser Jamil  1 , Dana Alameddine  2 , Mahmoud El Iskandarani  3 , Ankit Agrawal  4 , Aro D Arockiam  4 , Elio Haroun  4 , Heba Wassif  4 , Patrick Collier  4 , Tom Kai Ming Wang  5
Affiliations
Meta-Analysis

Cardiovascular Outcomes of Uric Acid Lowering Medications: A Meta-Analysis

Yasser Jamil et al. Curr Cardiol Rep. 2024 Dec.

Abstract

Background: Although hyperuricemia is a recognized risk factor for cardiovascular diseases, mixed results have been reported regarding the associations between uric acid-lowering medications and cardiovascular events. This meta-analysis compared the cardiovascular outcomes of different uric acid-lowering medications and placebo.

Methods: Following PRISMA guidelines, we searched OVID Medline, Embase, Web of Science, and Cochrane databases to identify potentially relevant articles until December 2023. Studies must be randomized or observational, report cardiovascular and mortality outcomes, and compare uric acid-lowering medications to placebo or each other. Data was analyzed using Revman (version 5.4) software.

Results: A total of 3,393 studies were searched, after which 47 studies were included, totaling 3,803,509 patients (28 studies comparing xanthine oxidase inhibitors (XOI) versus placebo, 17 studies comparing allopurinol and febuxostat, and 2 studies comparing XOI and uricosuric agents). Overall mean age was 57.3 years, and females comprised 20.8% of all studies. There were no significant differences between XOI and placebo for cardiovascular outcomes (mortality, myocardial infarction, major adverse cardiovascular events, heart failure, or arrhythmia). There was significant heterogeneity in all these pooled analyses. Comparing Allopurinol to Febuxostat, there was a lower risk of heart failure in febuxostat than allopurinol in 3 RCTs (OR 0.66, 95% CI 0.50-0.89, p = 0.006). Other cardiovascular outcomes were not different. Lastly, when comparing XOI and uricosuric agents, no significant differences in MI rates were evident.

Conclusion: XOI was not associated with reduced cardiovascular events compared to placebo. When comparing XOI agents, Febuxostat might reduce the risk of HF, but future studies are required to confirm the findings from the current study.

Keywords: Allopurinol; Cardiovascular disease; Meta-analysis; Uric acid.

PubMed Disclaimer

Conflict of interest statement

Declarations. Human and Animal Rights and Informed Consent: Not applicable Conflict of Interests: The authors declare no competing interests. Disclosures: None.

References

    1. Wang R, Song Y, Yan Y, Ding Z. Elevated serum uric acid and risk of cardiovascular or all-cause mortality in people with suspected or definite coronary artery disease: A meta-analysis. Atherosclerosis. 2016;254:193–9. - PubMed - DOI
    1. Zuo T, Liu X, Jiang L, Mao S, Yin X, Guo L. Hyperuricemia and coronary heart disease mortality: a meta-analysis of prospective cohort studies. BMC Cardiovasc Disord. 2016;16(1):207. - PubMed - PMC - DOI
    1. Saito Y, Nakayama T, Sugimoto K, Fujimoto Y, Kobayashi Y. Relation of lipid content of coronary plaque to level of serum uric acid. Am J Cardiol. 2015;116(9):1346–50. - PubMed - DOI
    1. Si K, Wei C, Xu L, Zhou Y, Lv W, Dong B, et al. Hyperuricemia and the risk of heart failure: pathophysiology and therapeutic implications. Front Endocrinol. 2021;12:770815. - DOI
    1. Kawasoe S, Kubozono T, Yoshifuku S, Ojima S, Oketani N, Miyata M, et al. Uric acid level and prevalence of atrial fibrillation in a Japanese general population of 285,882. Circ J. 2016;80(12):2453–9. - PubMed - DOI

MeSH terms

LinkOut - more resources